PS
Highly rated in
18
conditions
Highly rated in
18
conditions
Check Dr. Peter E. Schwartz's experience treating your condition:
About Dr. Peter E. Schwartz

Peter Schwartz is a Gynecologic Oncologist and an Oncologist in New Haven, Connecticut. Schwartz has been practicing medicine for over 56 years and is highly rated in 18 conditions, according to our data. His top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Ovarian Cancer, Hysterectomy, and Oophorectomy. He is licensed to treat patients in Connecticut.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 4 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Peter E. Schwartz it is best to call his office and ask if your insurance is accepted.


Call to see if your plan is accepted.
Locations
35 Park St, New Haven, CT 06519
Other Locations
1450 Chapel St, New Haven, CT 06511
Background & Education
Graduate Institution
Albert Einstein College Of Medicine Of Yeshiva University, 1966
Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in CT
Hospital Affiliations
Smilow Cancer Hospital At Yale New Haven
Waterbury Hospital
Bridgeport Hospital
Yale New Haven Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
View 3 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors